Yorvipath
Drug Endocrinology
NDC 73362-100-01
General payments
$1,943,341
Research payments
$1,458,391
Through program year 2025, $1,943,341 in general payments and $1,458,391 in research payments were reported against Yorvipath (Endocrinology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $1,925,802 | 10,810 |
| 2025 | Research | $1,458,391 | 1,130 |
| 2024 | General | $17,539 | 54 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 76 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 50 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
10,864 general · 1,130 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.